Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01039792 · ClinicalTrials.gov registry record · Phase 2

Trial of Methyl B12 on Behavioral and Metabolic Measures in Children With Autism

A Phase 2 study of Autistic Disorder, sponsored by University of California, San Francisco.

Completed
Registry status
Phase 2
Development phase
57
Enrollment target
1
Study location

NCT01039792: Completed Phase 2 study of Autistic Disorder, sponsored by University of California, San Francisco.

NCT01039792 is a Phase 2 study of Autistic Disorder that has completed, run by University of California, San Francisco. The registered enrollment target is 57 participants, below the 112-participant average among 27 other Autistic Disorder trials with a reported enrollment target (49% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01039792, a Phase 2 study of Autistic Disorder, has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
Phase 2
Development phase
57 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine whether the supplement Methyl B12 is effective in treating some of the symptoms of Autism.

Primary Outcome

PI assesses subject's change using the CGI-I measure. This is a 7-point Likert scale that assesses improvement of the patient's condition. Scores range from the worst score of 7 (Very much worse) to the best score of 1 (Very much improved). Lower scores are better on this scale, and indicate greater improvement.

Conditions Studied

Autistic Disorder

Interventions

  • DIETARY_SUPPLEMENT Placebo
  • DRUG Methyl B12

Study Locations (1)

California

  • UCSF - San Francisco

Trial Details

FieldValue
Enrollment Target 57 participants
Start Date 2010-01
Est. Completion 2013-11
Phase Phase 2
University of California, San Francisco

1,713 total trials

What the finished NCT01039792 record still lists

NCT01039792 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, below the 112-participant average among 27 other Autistic Disorder trials with a reported enrollment target (49% lower).

The record links to 1 condition, with Autistic Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01039792 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT01039792 about?

NCT01039792 is a clinical study titled "Trial of Methyl B12 on Behavioral and Metabolic Measures in Children With Autism". The purpose of this study is to determine whether the supplement Methyl B12 is effective in treating some of the symptoms of Autism.

What is the current status of trial NCT01039792?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2010-01. Estimated completion is 2013-11.

What conditions does trial NCT01039792 study?

This clinical trial studies the following conditions: Autistic Disorder.

What interventions are being tested in trial NCT01039792?

The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Methyl B12 (DRUG).

Who is sponsoring clinical trial NCT01039792?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01039792 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Autistic Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01039792's enrollment target sits among peer trials

57 15th of 27 higher than 13 of 27 other Autistic Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Autistic Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03521830 · 57 participants · Phase 2

    Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma

  • NCT03587701 · 57 participants · Phase 2

    Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease

  • NCT04104126 · 57 participants · NA

    Blood Flow Restriction Therapy in Achilles Injury

  • NCT04703842 · 57 participants · Phase 1

    Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01039792, the US trial registry maintained by the National Library of Medicine. NCT01039792 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.